De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Devyser Diagnostics Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Devyser Diagnostics heeft een totaal eigen vermogen van SEK367.9M en een totale schuld van SEK500.0K, wat de schuld-eigenvermogensverhouding op 0.1% brengt. De totale activa en totale passiva bedragen respectievelijk SEK489.8M en SEK121.9M.

Belangrijke informatie

0.1%

Verhouding schuld/eigen vermogen

SEK 500.00k

Schuld

Rente dekkingsratio	n/a
Contant	SEK 201.00m
Aandelen	SEK 367.90m
Totaal verplichtingen	SEK 121.90m
Totaal activa	SEK 489.80m

Recente financiële gezondheidsupdates

Devyser Diagnostics (STO:DVYSR) Is In A Strong Position To Grow Its Business

Feb 22

Recent updates

Analysts Just Made A Substantial Upgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) Forecasts

Jun 14

Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 27% But Many Are Still Ignoring The Company

Mar 20

Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported And Analysts Have Been Cutting Their Estimates

Feb 23

Devyser Diagnostics (STO:DVYSR) Is In A Strong Position To Grow Its Business

Feb 22

Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 28% But Many Are Still Ignoring The Company

Dec 09

These Analysts Just Made An Incredible Downgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) EPS Forecasts

Aug 30

Devyser Diagnostics AB (publ) (STO:DVYSR) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 14

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( SEK295.1M ) DVYSR } overtreffen de korte termijn passiva ( SEK67.1M ).

Langlopende schulden: De kortetermijnactiva DVYSR ( SEK295.1M ) overtreffen de langetermijnschulden ( SEK54.8M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: DVYSR heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van DVYSR is de afgelopen 5 jaar gedaald van 25% naar 0.1%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: DVYSR heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.

Voorspelling contante baan: Er zijn onvoldoende gegevens om te bepalen of DVYSR voldoende cash runway heeft als de vrije kasstroom blijft groeien of krimpen op basis van historische percentages.

Devyser Diagnostics Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Devyser Diagnostics (STO:DVYSR) Is In A Strong Position To Grow Its Business

Recent updates

Consensus EPS estimates fall by 18%

Chief Executive Officer recently bought kr324k worth of stock

Second quarter 2024 earnings released: kr1.41 loss per share (vs kr0.90 loss in 2Q 2023)

New minor risk - Shareholder dilution

Chief Executive Officer recently sold kr5.5m worth of stock

Analysts Just Made A Substantial Upgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) Forecasts

Devyser Diagnostics AB (publ) Appoints Thomas Eklund as Member of the Board of Directors

Chief Executive Officer recently bought kr299k worth of stock

First quarter 2024 earnings released: kr0.75 loss per share (vs kr1.23 loss in 1Q 2023)

Devyser Receives IVDR Approval for Post-Transplant Monitoring Software

Full year 2023 earnings: EPS misses analyst expectations

Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 27% But Many Are Still Ignoring The Company

Consensus estimates of losses per share improve by 66%

Devyser Diagnostics AB (publ) Announces Study Publication Demonstrating dd-cfDNA Detection in Dual Donor Kidney Transplant Patient

Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported And Analysts Have Been Cutting Their Estimates

Devyser Diagnostics (STO:DVYSR) Is In A Strong Position To Grow Its Business

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Insider selling

Devyser Diagnostics AB (Publ) Announces Michael Uhlin, CSO Joins Management Team as of February 1, 2024

Devyser Diagnostics AB (publ) to Report Fiscal Year 2023 Final Results on Apr 11, 2024

Devyser Diagnostics AB (publ) to Report Q1, 2024 Results on May 08, 2024

Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 28% But Many Are Still Ignoring The Company

Chief Executive Officer recently bought kr1.5m worth of stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Devyser Diagnostics AB (publ), Annual General Meeting, May 14, 2024

Consensus estimates of losses per share improve by 29%

Independent Director recently bought kr1.1m worth of stock

Consensus revenue estimates fall by 11%

These Analysts Just Made An Incredible Downgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) EPS Forecasts

New minor risk - Profitability

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Devyser's Ngs Products for Monitoring of Kidney and Stem Cell Transplanted Patients Receive IVDR Approvals

Devyser Launches Two New Genetic Testing Solutions for Hereditary Cancer

Devyser Announces its Deputy CEO and Founder Ulf Klangby Moves to Advisory Role

Chief Executive Officer recently bought kr105k worth of stock

Devyser Diagnostics AB Announces Approval of Devyser's RHD Product in Canada

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates upgraded to kr1.89 loss

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 1,989%

Less than half of directors are independent

Third quarter 2022 earnings released: kr0.55 loss per share (vs kr0.87 loss in 3Q 2021)

Devyser Diagnostics AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

Devyser Diagnostics AB (publ) Appoints John Murad as Vice President and General Manager in the US

Consensus EPS estimates fall by 66%

Second quarter 2022 earnings released: kr0.90 loss per share (vs kr0.94 loss in 2Q 2021)

Devyser Diagnostics AB (publ) to Report Q3, 2023 Results on Nov 09, 2023

Devyser Diagnostics AB (Publ) Appoints Camilla Wiberg as Chief HR Officer

Less than half of directors are independent

Devyser Diagnostics AB (publ) (STO:DVYSR) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Devyser Diagnostics AB (publ), Annual General Meeting, May 11, 2022

Less than half of directors are independent

Devyser Diagnostics AB (publ) Appoints Theis Kipling as Chief Commercial Officer

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Devyser Diagnostics AB (publ) to Report Q4, 2021 Results on Feb 24, 2022

Devyser Diagnostics AB (publ) (OM:DVYSR) agreed to acquire the remaining 70.1% stake in Smartseq S.R.L. from its three founders for €0.84 million.

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven